EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Type I interferon and cancer

Peter Holicek, Emma Guilbaud, Vanessa Klapp, Iva Truxova, Radek Spisek, Lorenzo Galluzzi, Jitka Fucikova iD

Immunological Reviews · 2024-01 · 321 (1) · 115-127

DOI: 10.1111/imr.13272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 04.09.2023. Verfasst von Peter Holicek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sotio Biotech, Prague, Czech Republic. Hauptthemen laut MEDLINE: Interferon Type I, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 152-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leukemia and Lymphoma Society, NIH/NCI, Sandra and Edward Meyer Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I interferon (IFN) is a class of proinflammatory cytokines with a dual role on malignant transformation, tumor progression, and response to therapy. On the one hand, robust, acute, and resolving type I IFN responses have been shown to mediate prominent anticancer effects, reflecting not only their direct cytostatic/cytotoxic activity on (at least some) malignant cells, but also their pronounced immunostimulatory functions. In line with this notion, type I IFN signaling has been implicated in the antineoplastic effects of various immunogenic therapeutics, including (but not limited to) immunogenic cell death (ICD)‐inducing agents and immune checkpoint inhibitors (ICIs). On the other hand, weak, indolent, and non‐resolving type I IFN responses have been demonstrated to support tumor progression and resistance to therapy, reflecting the ability of suboptimal type I IFN signaling to mediate cytoprotective activity, promote stemness, favor tolerance to chromosomal instability, and facilitate the establishment of an immunologically exhausted tumor microenvironment. Here, we review fundamental aspects of type I IFN signaling and their context‐dependent impact on malignant transformation, tumor progression, and response to therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Type INeoplasmsAntineoplastic AgentsHumansCytokinesTumor Microenvironment

Stichwörter der Autor:innen

CGASSTING1apoptotic cell deathimmunogenic cell deathinterferon-stimulated genespattern recognition receptors

Substanzen

Interferon Type IAntineoplastic AgentsCytokines

Autor:innen und Institutionen

  • Sotio Biotech, Prague, Czech Republic.
  • Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
  • Department of Radiation Oncology, Weill Cornell Medical College, New York, New York, USA.
  • Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Strassen, Luxembourg.
  • Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Sandra and Edward Meyer Cancer Center, New York, New York, USA.

ORCID-Profile: Jitka Fucikova

Förderung

  • Leukemia and Lymphoma Society
  • NIH/NCI
  • Sandra and Edward Meyer Cancer Center
  • Sotio Biotech
  • STARR Cancer Consortium
  • US DoD BCRP
  • Weill Cornell Medicine - Qatar
  • NCI NIH HHS

Zitieren

APA

Holicek, P., Guilbaud, E., Klapp, V., Truxova, I., Spisek, R., Galluzzi, L., & Fucikova, J. (2024). Type I interferon and cancer. Immunological Reviews, 321(1), 115-127. https://doi.org/10.1111/imr.13272

Vancouver

Holicek P, Guilbaud E, Klapp V, Truxova I, Spisek R, Galluzzi L, et al. Type I interferon and cancer. Immunological Reviews. 2024;321(1):115-127. doi:10.1111/imr.13272

BibTeX
@article{Holicek2024,
  author = {Holicek, Peter and Guilbaud, Emma and Klapp, Vanessa and Truxova, Iva and Spisek, Radek and Galluzzi, Lorenzo and Fucikova, Jitka},
  title = {Type I interferon and cancer},
  journal = {Immunological Reviews},
  year = {2024},
  volume = {321},
  number = {1},
  pages = {115--127},
  doi = {10.1111/imr.13272}
}
Kostenlos starten →